TargetBeta
ADRB1
adrenoceptor beta 1 · also ADRB1R · Adrenoceptors
2 programs in company-led studies act on ADRB1, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Epinephrinerule | Nasus Pharma | phase 4 | 175 running | ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3 | ChEMBL |
| Timololrule | AbbVie | phase 4 | 270 running | ADRB2 | ChEMBL |
Conditions their studies are in
- Anaphylaxis, 1 program
- Asthma, 1 program
- Chronic Urticaria, 1 program
- Glaucoma, 1 program
- Glaucoma, Open-Angle, 1 program
- Hemangioma, Capillary, 1 program
- Hypersensitivity, 1 program
- Respiratory Tract Infections, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027Epinephrine · Nasus Pharma · phase 4 · NCT06834165
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.